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Lesion-based targeting strategies underlie cancer precision medicine. However, biological
principles – such as cellular senescence – remain difficult to implement in molecularly
informed treatment decisions. Functional analyses in syngeneic mouse models and cross-
species validation in patient datasets might uncover clinically relevant genetics of biological
response programs. Here, we show that chemotherapy-exposed primary Eµ-myc transgenic
lymphomas – with and without defined genetic lesions – recapitulate molecular signatures of
patients with diffuse large B-cell lymphoma (DLBCL). Importantly, we interrogate the murine
lymphoma capacity to senesce and its epigenetic control via the histone H3 lysine 9 (H3K9)-
methyltransferase Suv(ar)39h1 and H3K9me3-active demethylases by loss- and gain-of-
function genetics, and an unbiased clinical trial-like approach. A mouse-derived senescence-
indicating gene signature, termed “SUVARness”, as well as high-level H3K9me3 lymphoma
expression, predict favorable DLBCL patient outcome. Our data support the use of functional
genetics in transgenic mouse models to incorporate basic biology knowledge into cancer
precision medicine in the clinic.
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Advanced stage solid tumors that are no longer solelysurgically curable, and most hematological malignancies,in principle, require systemic pharmacological anti-cancer
therapies1. Irrespective of their disseminated growth, some leu-
kemia and lymphoma entities are potentially curable by che-
motherapy, with treatment resistance, in turn, representing the
key determinant of patient death in hematological malignancies.
Although mostly developed on an empirical basis over many
decades, DNA-damaging agents have significant efficacy and will
remain the backbone of anti-cancer therapies for many tumor
entities in the future, and this especially applies to aggressive
lymphoma such as diffuse large B-cell lymphoma (DLBCL).
While standard “R-CHOP” immune-chemotherapy (i.e., the anti-
CD20 antibody rituximab plus cyclophosphamide [CTX], adria-
mycin [ADR], vincristine, and prednisone2) achieves long-term
disease control in about 60% of the DLBCL patients3,4, the out-
come of failing patients is, despite intense salvage regimens,
dismal5. Since the beginning of the millennium, transcriptome-
and genome-based profiling of DLBCL has led to much deeper
molecular insights in this entity6–15, but virtually all recent ran-
domized phase III trials, intended to enhance R-CHOP efficacy
by an additional agent and conducted in largely unselected
DLBCL patient populations, failed. Hence, the functional impact
of distinct mutations, molecular subtypes, and, in particular,
global therapy effector programs—namely apoptosis and senes-
cence—on patient long-term outcome remains, in general, rather
poorly understood and therapeutically underexploited.
Predicting drug responses and deciphering treatment failure is
of pivotal importance to improve treatment outcome in oncology.
Preclinical platforms for testing anti-cancer drug susceptibility
include cytotoxicity assays in established multi-passage cancer
cell lines, primary tumor cells grown in 2D- or 3D-cultures,
patient-derived xenograft (PDX) models in immunocompro-
mised mice, or syngeneic, orthotopically transplantable tumor
models in mice with normal immune functions16–19. We inves-
tigated here the Eµ-myc transgenic mouse as a tractable and
immune-competent model approximation to DLBCL that
allowed us to study treatment responses in a larger number of
primary lymphomas in a clinical trial-like fashion. Specifically,
Eµ-myc transgenic lymphomas exhibit clinical, histopathological
and genetic features of aggressive human B-cell lymphoma, are
transplantable, and grow system-wide at natural sites—i.e., typi-
cally in the lymph nodes (LN), the spleen, the BM, and the
peripheral blood, sometimes also in visceral organs—where they
shape their microenvironments and engage in host immune
interactions20–23. Upon lymphoma manifestation and adminis-
tration of therapy, drug, or radiation responses can be easily
monitored by clinical palpation of LN sites or whole-body ima-
ging techniques, especially if lymphoma cells (LC) are stably
fluorescence- or bioluminescence-engineered24,25. In the past, we
utilized this model to investigate the impact of candidate genes or
global effector programs, with particular interest in cellular
senescence, on treatment outcome via reverse genetics20–22,25–28.
Stress response programs such as apoptosis and cellular
senescence serve as important effector principles of anti-cancer
therapy29. Cellular senescence is an acutely stress-inducible cell-
cycle arrest condition that complements apoptosis as another
ultimate cell-cycle exit program30–32. The firm G1-phase arrest of
oncogene- or therapy-induced senescent (OIS, TIS, respectively)
cells is executed through the Retinoblastoma protein (Rb)/E2F
transcription factor-guided trimethylation at the lysine-9 residue
of histone H3 (H3K9me3), mediated, for instance, by the indir-
ectly Rb-bound H3K9 methyltransferase Suv39h1 (suppressor of
variegation 3–9 homolog 1, briefly “suvar”), thereby creating a
repressive chromatin environment in the vicinity of S-phase-
promoting E2F target genes33,34. However, dissecting TIS as a key
contributor to long-term outcome, and, even more, anticipating
the senescence response to a future therapy are particularly dif-
ficult in primary patient material, underscoring the need for
functional investigations in patient-predictive mouse models of
cancer35,36.
Hence, we explore here a transgenic mouse lymphoma model
in an unbiased forward genetics approach, dissect and compare
underlying genetics of drug (in)sensitivity across species, evaluate
cellular senescence as a drug effector program in the mouse, and
probe mouse model-derived senescence mediators and related
genetic classifiers as biomarkers of DLBCL patient survival—
functional investigations technically and ethically virtually
impossible to be solely conducted in cancer patients. In essence,
our approach seeks to bioinformatically extract predictive sig-
natures from outcome analyses in murine aggressive B-cell lym-
phoma models to inform precision medicine in DLBCL patients.
Results
Eµ-myc lymphomas recapitulate DLBCL treatment outcome.
To obtain array-based genome-wide gene expression profiles
(GEP) and document treatment responses of individual lym-
phomas, a larger series (n= 39) of primary B-cell lymphomas
that arose in Eµ-myc transgenic mice (hereafter referred to as
“control” lymphomas) were intravenously transplanted into two
wild-type recipient mice each (Fig. 1a). At the time well-palpable
LN enlargements had formed, a single dose of the alkylating
chemo-agent CTX was intraperitoneally administered, and
responses were monitored at least twice a week. Consistent with
the high initial chemo-sensitivity of most lymphoma patients to
their first-line induction therapy, all mice achieved a complete
remission (CR) by clinical criteria (see Methods for details)
within a few days after CTX application, collectively forming the
treatment-sensitive [“SENS”] group of primary lymphomas at
diagnosis (Fig. 1a). In the range of the progressing fraction of
DLBCL patients treated with standard R-CHOP induction ther-
apy, 35 of the 78 mice presented with re-growing LN during the
100-day observation period (i.e. the “relapse-prone [RP]” group),
while about half of the cohort (i.e., the NR group) remained
relapse-free (comparable to the 47% 5-year event-free survival for
R-CHOP patients in major clinical trials37,38), and was con-
sidered cured, therefore designated “never relapse [NR]” lym-
phomas (Fig. 1b, plateau of the green curve). Interestingly, time-
to-relapse (TTR) was very similar among most of those paired
recipients that were transplanted with the same primary lym-
phoma (Supplementary Fig. 1a), indicating that the key infor-
mation determining treatment outcome is encoded in the tumor
cell population, albeit not excluding an instructive impact the
tumor cells may have on other host components. When retreated
at the time of relapse with a second application of CTX, all mice
entered a CR again, but none achieved long-term disease control
anymore (Fig. 1b, blue curve). Moreover, the recapitulation of the
standard CHOP regimen in our lymphoma-bearing mouse cohort
produced the same long-term outcome: virtually every primary
lymphoma that relapsed after CTX also recurred after CHOP, and
lymphomas achieving lasting remissions in response to CHOP
were also cured by CTX alone (Supplementary Fig. 1b). Mice
reprogressing after two rounds of CTX were subjected to a third
dose of the same agent, again resulting in even shorter durations
of response and no lasting disease control (Fig. 1b, red curve).
Eventually, if exposed to additional rounds of CTX, mice exhib-
ited at best a “no change” situation or presented with “progressive
disease”, i.e., no shrinkage or even continuous growth despite
therapy. In essence, we established a transgenic lymphoma
treatment platform that resembles some clinical results observed
in DLBCL patient cohorts in response to CHOP-based therapies,
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Fig. 1 The Eµ-myc mouse lymphoma model recapitulates molecular signatures and some clinical features of human DLBCL. a Utilization of the Eµ-myc
model in a clinical trial-like fashion. Eµ-myc lymphomas were transplanted into wild-type recipients and treated with CTX upon lymphoma formation. After
initial remission, tumors that relapsed (RP, unlike those that did not [NR]) were retreated. Lymphomas were considered clinically resistant after a third
relapse (RES). b Tumor-free survival of CTX-treated mice after first(-line) treatment (n= 76, green line), after second treatment (n= 31, blue line), and
after third treatment (n= 28, red line). Two mice per lymphoma were monitored for response. c Principal components analysis based on signature genes
separating patients with Burkitt’s lymphoma (n= 98) from those with DLBCL (n= 1305) in different datasets and Eµ-myc lymphomas (n= 154). Each
dataset was separately row (gene) mean-centered and scaled to unit variance before being combined in a single dataset. The larger white-bordered points
denote the centroid of each lymphoma type. d Tumor-free survival of CTX-treated mice bearing ABC-like (n= 10), GCB-like (n= 24) or unclassified (n=
42) Eµ-myc lymphomas. Two mice per lymphoma were used. e Pattern comparison of multiple GSEA results of the three distinct CCC subgroups (as
indicated) with one compared against the two others for DLBCL cases and Eµ-myc lymphomas. Each column shows group-specific upregulated gene sets.
The color code denotes analyses of each CCC group against the rest. NES normalized enrichment score.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-17467-z ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:3651 | https://doi.org/10.1038/s41467-020-17467-z | www.nature.com/naturecommunications 3
and that culminates, if no cure is achieved, in a progressive
shortening of response durations, ultimately leading to full-blown
chemoresistance (“RES”; Fig. 1a).
DLBCL classifiers delineate corresponding murine subgroups.
Transcriptome analyses unveiled two distinct cell-of-origin
(COO) signatures in DLBCL, representing a germinal center B-
cell (GCB) and an activated B-cell (ABC) subtype6,8, with an
inferior outcome consistently reported for the ABC subtype in
many trials applying CHOP or R-CHOP regimens to DLBCL
patients8. We previously recapitulated COO-related differences in
NF-κB activity in Eµ-myc lymphomas27,39. To enhance statistical
robustness and to increase biological diversity, we combined GEP
data from our 39 primary lymphomas with a published GEP set
obtained from 115 additional primary Eµ-myc lymphomas40,
comprising a total of 154 samples. Using principal component
analysis and the murine homologue of a human gene classifier
built to distinguish DLBCL from Burkitt’s lymphoma (BL)41, we
first verified that Eµ-myc lymphomas share transcriptional fea-
tures with DLBCL and are distinct from molecular BL (Fig. 1c).
Based on cardinal molecular features of the respective COO
subtypes and applying the linear predictor score (LPS) classifi-
cation method presented by the Staudt group for DLBCL42, we
developed a 21-gene murine version of the human 25-gene
classifier, which was instrumental to recognize distinct Eµ-myc
lymphoma subtypes, i.e., a GCB-like, an ABC-like and a third,
unclassified group with ABC/GCB-overlapping features (Supple-
mentary Fig. 1c). Importantly, TTR stratified by the GCB-like vs.
ABC-like COO status of SENS lymphomas demonstrated a sig-
nificantly superior long-term outcome to CTX in the GCB-like
arm, thereby recapitulating the predictive role of the COO status
in human DLBCL8 (Fig. 1d). Thus, Myc-driven mouse lympho-
mas comprise biological features that resemble human GCB- and
ABC-type DLBCL, in which high-level Myc expression is also a
prominent and widely detectable feature13,43.
Additional transcriptional DLBCL heterogeneity with asso-
ciated distinct functional biological properties, albeit not
necessarily different outcomes to standard therapy, was captured
in the “comprehensive consensus cluster (CCC)” classification by
the Shipp group44. Hence, we asked whether the CCC subtypes
“B-cell receptor (BCR)/proliferation” signaling, “oxidative phos-
phorylation (OxPhos)” metabolism, and “host response (HR)”
immunology would also be applicable to primary Eµ-myc
lymphomas, separating them into these three distinct subclasses
as well. Using a three-class extension of the LPS method on the
Eµ-myc GEP data, this was indeed the case (Supplementary
Fig. 1d). Remarkably, CCC class-specific upregulated gene sets,
selected by GSEA in human DLBCL comparing each subgroup
against the other two, were similarly enriched in the Eµ-myc
model (Fig. 1e; DLBCL vs. Eµ-myc patterns in each of the three
CCC subtypes). In essence, Eµ-myc transgenic lymphomas are
molecularly heterogeneous and share prominent biological
features related to distinct subclasses of human DLBCL,
suggesting their suitability as a faithful functional model for
certain features of the corresponding human disease.
Molecular data possess predictive power across species. We
further sought to determine whether a strictly outcome-based
(i.e., COO- or CCC-agnostic) DLBCL signature might also be
predictive for Eµ-myc lymphomas and vice versa. We first ana-
lyzed GEP data from our 39 primary SENS Eµ-myc lymphomas,
and utilized the most strongly differentially expressed genes to
separate curable (i.e., NR) from relapsing (i.e., RP) lymphomas
(Supplementary Fig. 2a). A similar approach was used to distin-
guish at diagnosis DLBCL patients that achieved lasting
remissions from those failing therapy (Supplementary Fig. 2b).
Next, we selected genes which were commonly upregulated in
matching response groups (i.e., progressors vs. nonprogressors)
in both species. These genes were subsequently applied to the
outcome-annotated expression data of murine and human lym-
phomas, and two top-clusters (cluster 1 and 2) were identified in
each species by hierarchical cluster analysis (Fig. 2a, b; grey and
black bars). These clusters were significantly correlated with the
respective response groups (Fig. 2a, b; colored bars and Supple-
mentary Fig. 2c, d). Strikingly, the two clusters sharply separated
both CTX-exposed Eµ-myc lymphomas for significantly different
TTR (Fig. 2c), and R-CHOP-treated DLBCL patients regarding
their progression-free and overall survival (PFS and OS, respec-
tively; Fig. 2d). Hence, individual transcriptome data linked to
clinical response information can be utilized to generate gene
stratifiers that discriminate good from poor risk lymphomas
across species. However, transcriptome-based data not linked to
functional biological insights may not suffice to decipher the
contribution of distinct treatment effector principles, especially
cellular senescence, in long-term outcome after anticancer
therapies.
Probing drug-induced senescence in the Eµ-myc lymphoma
model. Accordingly, we seek here to specifically address senes-
cence as a drug-evoked response program, to link its genetic
underpinnings to transcriptome-informed outcome data in
murine and human lymphoma settings, and to develop predictors
of the senescence contribution to patient survival. Starting from a
mouse model platform with defined senescence-compromising
gene defects, primary Eµ-myc transgenic LC, stably over-
expressing Bcl2 (as naturally detected at high levels in many
lymphomas including DLBCL15) to block drug-induced apopto-
sis, enter TIS in vitro and in vivo, if senescence-essential gene loci
such as Suv39h1 or p53 alleles were not deleted22,25,28 (Fig. 3a,
Supplementary Fig. 3a, b). When investigated in a trial-like
fashion in the absence of an intact apoptotic response, we
observed a dramatically shortened OS of the mouse cohort
bearing senescence-incapable Suv39h1-deficient (hereafter refer-
red to as Suv39h1−) lymphomas, thereby suggesting a critical role
for TIS in the long-term outcome to therapy (Fig. 3b).
Next, we asked whether senescence would also affect outcome
when Bcl2 is not exogenously overexpressed. Importantly, non-
Bcl2-engineered Suv39h1− LC presented—like control lympho-
mas, but different from apoptosis-compromised p53null lym-
phomas—with exquisite apoptotic drug sensitivity, thus
highlighting their selective senescence defect while apoptosis
remains intact (Supplementary Fig. 3c). Accordingly, mice
harboring Suv39h1-deficient or proficient lymphomas typically
entered a clinical CR in response to a single administration of
CTX in vivo (i.e., all mice presented tumor-free at time-point 0
post CTX; Fig. 3c). Interestingly, when we examined three
lymphoma compartments—the bone marrow (BM), the LN and
the spleen (SP)—with respect to potentially remaining LC by Eµ-
myc transgene-specific polymerase chain reaction (PCR) in a
“minimal residual disease (MRD)”-like analysis 10 days after
CTX, we found most of the control lymphoma mice-derived
samples still positive, while none of the probes of the Suv39h1−
group produced an MRD signal (Fig. 3d). Spleen sections were
obtained to visualize remaining LC in situ, and unveiled much
smaller islands of persistent cells in the Suv39h1− cohort (Fig. 3e).
Though, the vast majority of these cells scored Ki67+/H3K9me3−
by co-immunostaining—in stark contrast to the virtually Ki67-
negative but H3K9me3-positive, hence, senescent splenic lym-
phoma residues in the control group, indicating not only a
massive drop in overall tumor burden, but an important
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qualitative state switch of the remaining Suv39h1-proficient LC
(Fig. 3e). Matching the day-10 MRD data, mice of the Suv39h1−
group scanned by whole-body luciferase imaging regarding their
tumor burden presented with virtually no remaining lymphoma
load, while control lymphoma-bearing mice produced positive
signals at this time-point (Fig. 3f and Supplementary Fig. 3d).
However, as shown for a day-30 comparison, Suv39h1−
lymphomas rapidly progressed out of this complete molecular
response (i.e., below-detectability) situation, whereas mice of the
control group rather turned, with slow kinetics, luminescence
imaging-negative (Fig. 3f, Supplementary Fig. 3d), thereby
pointing toward a potential clinical pitfall when utilizing MRD
or imaging diagnostics in a certain time slot of a senescence-
dominated residual tumor load (further in line with the
previously reported and equally unanticipated strong glucose
avidity of robustly growth-terminated senescent lymphoma-
bearing mice by positron emission tomography25). The data also
imply a competition between the execution of apoptosis or
senescence on the cellular level of control tumors, whose nature
might be stochastic or controlled by yet to-be-determined
regulators. Importantly, when we compared clinical outcome in
the absence of an apoptotic block, mice bearing Suv39h1-deficient
lymphomas had a much shorter TTR and a much higher fraction
of lymphomas that relapsed within the observation period of
100 days (Fig. 3c). Thus, we conclude that cellular senescence
critically contributes to the long-term outcome after chemother-
apy in both apoptotically compromised and competent lym-
phoma settings.
Cross-species investigation of the H3K9 senescence relay.
While the histone methyltransferase Suv39h1 operates as an
essential mediator of OIS and TIS in mouse lymphoid
cells23,25,28,34, other H3K9-active methyltransferases may com-
pensate for loss of this moiety in different tissues and species.










































































Fig. 2 DLBCL and Eµ-myc lymphoma share predictive genes sets. a Heatmap of 39 primary Eµ-myc lymphomas based on genes being commonly
differentially expressed in non-progressing vs. relapsing DLBCL patients. b Same as in (a), but for 470 DLBCL patients (GSE31312). Eµ-myc lymphomas
and DLBCL patients were separated into two clusters by hierarchical clustering using Pearson’s distance correlation and complete linkage. Because of little
very high and very low z-scores, they were restricted to the interval [−5,5] after hierarchical clustering for presentation purposes only. c Tumor-free
survival of CTX-treated Eµ-myc lymphomas stratified by two hierarchical clusters (ncluster 1= 34, ncluster 2= 42) as shown in (a). Two mice per lymphoma
were used. d Progression-free and overall survival of R-CHOP-treated DLBCL patients stratified by the two hierarchical clusters as shown in (b) (ncluster 1=
297, ncluster 2= 173).
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therefore asked, in turn, whether overexpression of two structurally
unrelated H3K9me3-active demethylases, namely LSD1 (a.k.a.
AOF2 or KDM1A) and JMJD2C (a.k.a. GASC1 or KDM4C),
which we recently found to cancel OIS in melanomagenesis45,
and which were detected at elevated levels in numerous tumor
entities46–51, might also counter TIS. Stable transfer of LSD1 and
JMJD2C genes into control;bcl2 lymphomas, similar to
inactivation of Suv39h1, resulted in sharply reduced levels of the
H3K9me3 mark and the senescence-associated cyclin-dependent
kinase inhibitor p16INK4a by immunoblot analysis, and impaired
ADR-induced senescence in vitro, while leaving drug-induced
DNA damage response signaling via γ-H2AX and serine-18-
phosphorylated p53 (p53-P-Ser18) intact (Fig. 4a, Supplementary
Fig. 4a), resulting in demethylase-unaffected apoptotic death in
IHC GFP IHC GFP
control;bcl2 Suv39h1¯;bcl2
83.8% ± 8.7 83.7% ± 7.8
11.7% ± 12.0 14.2% ± 11.1
32.7% ± 4.5 73.3% ± 7.1
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Fig. 3 Defective senescence but intact apoptosis accounts for temporarily deeper responses of Suv39h1-deficient lymphomas. a Ki67, SA-β-gal activity
and H3K9me3 IHC analyses of lymphoma sections, plus whole-body fluorescence scans of mice bearing GFP-tagged control;bcl2 or Suv39h1−;bcl2
lymphomas. Results show mean percentages of cells positive for the respective markers in situ after a 5-day CTX exposure or those that remained
untreated ± s.d. (n= 3 technical replicates per group). b Overall survival of mice bearing Suv39h1−;bcl2 (n= 21, red line) or control;bcl2 (n= 24, black line)
lymphomas after CTX treatment. c Tumor-free survival (i.e., TTR) of mice bearing Suv39h1− (n= 18, red line) or control (n= 27, black line) lymphomas
after CTX treatment. d Eµ-myc transgene-specific PCR in Suv39h1- and control Eµ-myc lymphomas prepared from bone marrow (BM), lymph-node (LN), or
spleen (SP) from untreated mice (as a positive control) and 10 days after CTX treatment. Shown are analyses in mice bearing n= 8 individual lymphomas.
Original photomicrographs are presented in Supplementary Fig. 7. e Spleen sections stained for Ki67 and H3K9 in B220-positive lymphomas from
Suv39h1− or control mice. Numbers indicate mean percentages of cells positive for the respective marker in situ 10 days after CTX administration ± s.d.
(shown are representative photomicrographs of n= 3 biological replicates per group). f Representative whole-body luciferase imaging of mice harboring
Suv39h1− vs. control lymphoma (not bcl2-engineered) before treatment as well as 10 and 30 days after CTX treatment (n= 3 biological replicates per
group [see also Supplementary Fig. 3d]). All scale bars in this figure represent 50 µm.
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non-Bcl2-protected lymphomas (Supplementary Fig. 4b). As
observed for mice bearing Suv39h1−;bcl2 lymphomas, those
carrying control;bcl2 lymphomas engineered to stably over-
express either LSD1 or JMJD2C presented with very modest
senescence induction, no significant enhancement of the
H3K9me3-positive cell fraction, and a dramatically shortened OS
after CTX therapy when compared to the respective vector con-
trol group, thus further underscoring the importance of an
effective H3K9me3-governed senescence response for long-term
disease control (Fig. 4b, c, Supplementary Fig. 4c). Moreover, SA-
β-gal activity reached much higher levels in ADR-exposed LSD1;
bcl2 lymphomas if co-treated with the LSD1 inhibitor 2-PCPA-1a
in vitro (Supplementary Fig. 4d), similarly to the high SA-β-gal
activity induced by CTX exposure under 2-PCPA-1a co-
treatment in vivo (Fig. 4d).
Next, we tested whether treatment responsiveness of Myc-
driven control lymphomas that formed in the absence of any
engineered H3K9me3-erasing moiety would relate to their
endogenous H3K9 demethylase expression status. To investigate
this, we focused on genes with H3K9-specific histone demethylase
– + – + – + – +ADR
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activity (GO:0032454). Indeed, we found TIS much weaker in
control lymphomas with globally high expression levels of H3K9-
active demethylases, while the senescence response, and, accord-
ingly, the fraction of H3K9me3-positive cells detected by
immunostaining could be restored to an extent otherwise seen
in low-level H3K9 demethylase expressers by treatment with the
LSD1 inhibitor 2-PCPA-1a in vivo (Fig. 4d, Supplementary
Fig. 4e). Moreover, a high endogenous H3K9 demethylase status,
among others composed of LSD1 and JMJD2C expression levels,
not only predicted senescence restoring-susceptibility to the LSD1
inhibitor 2-PCPA-1a but equally to the JMJD2 inhibitor IOX1,
while neither inhibitor enhanced ADR-inducible senescence in
lymphomas with low endogenous H3K9me3 demethylase status
(Supplementary Fig. 4f). Notably, mice harboring individual
lymphomas with global H3K9 demethylases expression above
median presented with a significantly shorter TTR (Fig. 4e).
Remarkably, when probing the transcriptome datasets of DLBCL
patients for the humanized version of this H3K9 demethylase
stratifier, a significantly shorter PFS was unveiled in elderly
DLBCL patients if H3K9 demethylases were expressed above
median in their lymphoma samples (Fig. 4f). Since we expected
the activities of LSD1, JMJD2C and related demethylases to
converge at the H3K9me3 mark, we explored the
H3K9me3 status in situ as a putative biomarker of long-term
outcome to treatment. Indeed, both the Eµ-myc cohort and
DLBCL patients with high H3K9me3 expression in their
lymphoma sections exhibited a significantly better long-term
outcome to therapy when compared to those with H3K9me3
detectability below median (Fig. 4g, h). Hence, our data highlight
TIS as an H3K9me3-governed outcome-improving drug effector
mechanism first discovered and functionally dissected in murine
lymphomas, and subsequently confirmed in human large B-cell
lymphomas. Moreover, the endogenous H3K9 demethylase
genetics of DLBCL imply that different baseline expression levels
of the H3K9me3 mark as a readout of alterations acquired during
lymphomagenesis prior to any drug encounter may serve as a
predictive biomarker of long-term outcome to therapy.
Senescence impairment plays a role in treatment failure. To
approach our ultimate goal of a TIS-focused genetic predictor in
lymphoma, we defined an in vitro-senescence signature based on
genes being differentially expressed between ADR-senescent
control;bcl2 vs. equally ADR-exposed Suv39h1−;bcl2 and, hence,
senescence-incapable, or untreated Bcl2-infected lymphomas
(Fig. 5a). Next, we probed whether RES lymphomas typically
present with a molecular senescence defect by applying the in
vitro-senescence signature to our clinical trial-like mouse cohort
as an approximation to their senescence susceptibility (Fig. 5b;
using the LPS classifier method and the in vitro-TIS dataset
(Fig. 5a) as training data). Although TIS manifests with slow
kinetics as a full-featured biological condition in response to
DNA-damaging therapy, we hypothesized that early, albeit subtle
senescence-reminiscent molecular changes might already become
detectable within hours after drug exposure. Indeed, GSEA
highlighted the proximity of 4-h-CTX-in vivo-challenged senes-
cence-capable Eµ-myc lymphomas without Bcl2 protection and
5d-ADR-in vitro-senescent bcl2-engineered lymphomas based on
similar ES of a large number of common gene sets in their
expression profiles (Fig. 5c). If TIS contributes to superior long-
term outcome, we further suspected that senescence inducibility
might be more profound in curable lymphomas at diagnosis and
selected against in relapsed lymphomas. Hierarchical cluster
analysis from our clinical trial-like mouse model based on 4-hour-
CTX administration in vivo further supported our hypothesis that
RES lymphomas were predicted to have a senescence-incapable
phenotype (Supplementary Fig. 5; note virtually no overlapping
red- and black-labeled cases). Importantly, when applying the LPS
classifier as a TIS score, we found RES lymphomas, unlike the
SENS lymphoma groups, to be strongly skewed toward a Suv39h1-
deficient, hence, senescence-defective pattern in response to the 4-
h CTX challenge in vivo (Fig. 5d). Strikingly, when we next
classified each individual lymphoma in the CTX-exposed condi-
tion as either a “senescence responder” (TIS score > 0.8), a
“senescence non-responder” (TIS score < 0.2) or “unclassifiable”
(0.8 ≤ TIS score ≥ 0.2), the LPS/TIS score unveiled a significantly
superior long-term outcome (TTR) for yet-to-be-treated lym-
phomas belonging to the senescence responder group (Fig. 5e).
Moreover, our cross-species strategy also linked the GCB subtype
of DLBCL samples at diagnosis, i.e. prior to any drug encounter, to
a set of TIS-upregulated genes, thereby matching our previous
experimental observation of a particularly strong TIS capacity in
GCB-like and Bcl2-overexpressing, but not in ABC-like Eµ-myc
lymphomas with their enrichment of “TIS down-regulated” and
proliferation-associated gene sets27 (Fig. 5f). Intriguingly, the more
senescence-prone GCB subtype also appeared to be tran-
scriptionally skewed toward an adult tissue stem cell (ATSC)
signature in both murine and human lymphomas, thereby
expanding on our recently reported finding on senescence-
associated stemness in DLBCL28. Thus, early molecular changes
detectable in response to CTX treatment seem to anticipate a later
biologically fully established senescence response.
“SUVARness” predicts long-term outcome in mice and men.
Finally, we sought to utilize senescence-related transcript
Fig. 4 The H3K9me3 mark operates as a central, outcome-relevant senescence relay. a Western blot analysis of senescence-related proteins in Bcl2-
protected LSD1- or JMJD2C-overexpressing, Suv39h1-deficient and control lymphomas after 5 days of ADR treatment in vitro or left untreated. Samples
are representative of each genotype (n > 3). Original photomicrographs are presented in Supplementary Fig. 8. b Lymphoma sections of CTX-treated mice
bearing Bcl2-protected JMJD2C- or LSD1-overexpressing vs. control lymphomas stained for SA-β-gal. Numbers indicate mean percentages of cells
positive ± s.d. (shown are representative photomicrographs of biological replicates, n= 4 primary lymphomas for control;untreated, n= 5 for control;CTX,
n= 3 for LSD1;untreated, n= 4 for LSD1;CTX, n= 4 for JMJD2C;untreated, n= 4 for JMJD2C;CTX). c Overall survival (OS) in CTX-treated mice bearing
Bcl2-protected JMJD2C (n= 11, orange line)-, LSD1 (n= 10, blue line)-overexpressing or control (n= 14, black line) lymphomas. d Tumor sections of CTX-
or CTX-plus-2-PCPA-1a-treated mice bearing lymphomas with low or high H3K9-active demethylases (GO:0032454) expression levels stained for SA-β-
gal. Numbers indicate mean percentages of cells positive ± s.d. (shown are representative photomicrographs of n= 3 biological replicates per group). “*”
represents statistical significance by unpaired t test, p= 0.0129 (high;CTX vs. high;CTX+ 2-PCPA-1a) or p= 0.0339 (high;CTX vs. low;CTX). e Tumor-
free survival of CTX-treated mice stratified by median expression of genes that belong to the GO term “histone demethylase activity (H3-K9 specific)”
(GO:0032454). Two mice per lymphoma were used. Above median: n= 37 (black line), below median: n= 39 (grey line). f Progression-free survival (PFS)
of elderly (>63 years; with their aged and presumably more senescence-prone lymphoma cells) R-CHOP-treated DLBCL patients (GSE31312) stratified as
in (e). Above median: n= 116 (black line), below median: n= 117 (grey line). g Tumor-free survival of CTX-treated mice bearing Eµ-myc lymphomas with
high (n= 28, black line) or low (n= 31, grey line) levels of the H3K9me3 mark. h OS of R-CHOP-treated DLBCL patients bearing lymphoma with high (n=
18, black line) or low (n= 17, grey line) levels of the H3K9me3 mark. All scale bars in this figure represent 100 µm.
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information obtained in untreated lymphoma samples as a tool to
predict long-term outcome. Specifically, we generated a signature
named “SUVARness” (in scientific proximity to the term
“BRCAness” invented for BRCA1/2 wild-type tumors that share
molecular features of BRCA-mutant malignancies52, albeit
composed here as a transcriptional signature), consisting of TIS
upregulated genes, thus marking the conceptual opposite of the
senescence-compromising Suv39h1 deficiency in lymphoma
(Fig. 5a). We found this gene set strongly enriched in TIS control;
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4h CTX in vivoTIS in vitro
Fig. 5 Senescence defects account for treatment failure. a Heatmap of differentially expressed genes (p value < 0.01, log-FC > 1) comparing in vitro-ADR-
treated control;bcl2 or ADR/4OHT-double-treated Suv39h1:ER;bcl2 senescent (TIS) to ADR-treated Suv39h1− or Suv39h1:ER;bcl2 senescence-incapable,
or untreated non-senescent lymphomas (collectively 47 lymphomas). b Heatmap and associated probability of TIS (black line) vs. no senescence (i.e.,
proliferating, grey line) in CTX-treated lymphomas based on LPS classification using data in (a), which had 85.1% overall accuracy in a tenfold cross
validation of the in vitro-training data. c Heatmap of GSEA Normalized Enrichment Scores (NES) compiled of overall 47 5d ADR-in vitro-treated senescent
control;bcl2 lymphomas vs. non-senescent untreated and Suv39h1−;bcl2 or non-4OHT-exposed Suv39h1:ER;bcl2 senescence-incapable lymphomas
compared to 54 4 h-in vivo-CTX-treated vs. 55 untreated lymphomas. Clustering was performed using Euclidean distance. Senescence-related gene sets
are shown, some of them specifically indicated70. d Probability of a TIS phenotype according to the LPS classification (cf. panel b, black line) of 4 h-CTX-
treated or untreated lymphomas belonging to the indicated response groups (n= 20 CTX NR, n= 19 CTX RP, n= 15 CTX RES, n= 20 native NR, n= 19
native RP, n= 16 native RES). Higher TIS scores represent a stronger senescence likelihood, while lower scores indicate a proliferating phenotype. Box-and-
whisker plot showing the median (black line inside the box), upper and lower quartile (box edges), minima and maxima (whiskers), and outliers (dots). The
p value was calculated using the Kruskal–Wallis rank-sum test. e Tumor-free survival (TTR) of mice bearing senescence responder (TIS score > 0.8; n=
42), non-responder (TIS score < 0.2; n= 38) or unclassified (0.8≤ TIS score≥ 0.2; n= 22) Eµ-myc lymphomas as determined from the LPS classification
(based on the TIS status in the 4 h-CTX-exposed condition [cf. panel d]). Two mice per lymphoma were used. f GSEA NES results comparing ABC-like to
GCB-like subtypes in DLBCL patients (ABC/GCB training set from GSE10846, n= 150) and Eµ-myc lymphomas (dataset as used in Fig. 1, ABC/GCB
classified, n= 95).
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(Fig. 6a, first panel), and, likewise, strongly up in treatment-naïve
NR Eµ-myc lymphomas in vivo (Fig. 6a, second panel), as well as
in newly diagnosed DLBCL samples of two independent cohorts
of patients who achieved lasting remissions, when being com-
pared to RP mouse or human relapsed/refractory lymphomas,
respectively (Fig. 6a, right panels). Based on these GSEA analyses,
we defined a “core SUVARness” signature, commonly present in
these GSEA’s leading edges (i.e., the region from the top of the
gene list to the enrichment score [ES] profile peak position),
consisting of 22, notably largely proliferation-independent and
partly cell–cell/host immune interaction-relevant genes
(Table S1), which might serve as a biomarker that anticipates
treatment outcome (Fig. 6a). Accordingly, stratification of SENS
Eµ-myc lymphoma based on the average expression of this core
SUVARness signature predicted tumor-free survival, whereby
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superior survival (Fig. 6b). Cross-species application of a huma-
nized version of the core SUVARness senescence classifier to the
treatment-naïve transcriptome datasets of two independent
human cohorts comprising several hundreds of R-CHOP-treated
DLBCL patients also marked a much better PFS and OS of the
higher-expressing half of these patients (Fig. 6c, d, Supplementary
Fig. 6a, b). This was further validated in two independent CHOP-
treated DLBCL cohorts (Supplementary Fig. 6c, d). In essence,
our results highlight the power of the Eµ-myc transgenic mouse
lymphoma model to unveil the importance of senescence, namely
H3K9me3-governed SUVARness, in the course of human DLBCL
treatment, equipping us with a molecular stratifier that unveils
senescence susceptibility already at diagnosis in the patient sub-
group that experiences significantly superior long-term outcome.
Discussion
The molecular in-depth dissection of large sample numbers
across most cancer entities in general and DLBCL in particular
has led to a variety of genetically determined subgroups6–15. With
the approach presented here, we add a biological and dynamic
layer to the detailed but static profiling data obtained from
patients at diagnosis. Demonstrating the genetic and clinical
proximity of primary Eµ-myc transgenic mouse lymphomas to
DLBCL provided the basis to further interrogate them with
defined genetic defects in the biological feature of interest, or as
unmanipulated samples in a clinical trial-like format, out of
which we derived senescence-determining gene signatures whose
humanized homologues proved predictive when applied to hun-
dreds of DLBCL patients’ data consisting of molecular profiles
and the respective clinical outcome information post-standard
therapy at resolution of the individual patient. Specifically, we
were able to show that these lymphomas recapitulate genetic
features of previously established DLBCL subtypes such as the
HR/OxPhos/BCR consensus clusters and the clinically routinely
utilized distinction by COO into ABC and GCB subtypes6,42,44.
An important deliverable from this study is the humanized
version of the core TIS upregulated gene set that links senescence
susceptibility during subsequent therapy to improved long-term
outcome in unselected DLBCL patients (cf. Fig. 6c, d, Supple-
mentary Fig. 6a, b). We further applied this classifier of
SUVARness, based on the original Suv39h1 liability of
senescence25,34, to very recently reported novel DLBCL subsets,
termed clusters 0–5 (C0–C5), that were determined by a com-
prehensive in-depth genetic analysis of more than 300 primary
DLBCL cases14. When probing individual clusters regarding their
SUVARness, we found this outcome-predictive gene set to be
specifically enriched for in C0, C1, and C4, while it was pro-
foundly downregulated in C2, C5, and to a lesser extent in C3
(Fig. 6e). Thereby, SUVARness is linked to senescence-
reminiscent features such as a SASP-like pro-inflammatory
immune infiltrate (C0), enhanced NOTCH and NF-κB activity
(C1), and elevated RAS/BRAF/MEK signaling (C4), while p53,
INK4a/ARF, or Rb inactivation reflect senescence-incapable
genotypes in the SUVARness-negative cluster 2 (ref. 22). Fur-
ther senescence-focused investigations are needed regarding the
role of MyD88–L265P mutations as one of the leading lesions in
cluster 5 (C5), and the position of cluster C3, a strongly GCB
subtype-enriched cluster with frequent IgH enhancer/bcl2 trans-
locations, the constellation for which we previously showed the
NF-κB-hyperactive subset to be associated with senescence sus-
ceptibility27. Strikingly and further in support of the excellent
outcome data presented here for various independent
SUVARness-high DLBCL patient cohorts, grouped clusters 0, 1,
and 4 were just reported to achieve a superior outcome (PFS)
when compared to clusters C3/C5 (79% vs. 49% 5y-PFS, p=
0.002; ref. 14).
Importantly, while this study pinpointed with SUVARness the
ability to execute senescence as a tumor-controlling feature that
accounts for improved long-term outcome to therapy when
compared to tumors lacking such ability, TIS may also have
detrimental implications. We recently discovered reprogramming
of bulk tumor cells into cancer stem cells as the result of profound
epigenetic remodeling in senescence28, and reported that senes-
cent cells may occasionally re-enter the cell-cycle by losing
expression of senescence-essential gene moieties or gaining suf-
ficient expression of senescence-countering gene activities45.
Undoubtedly, senescence serves as a beneficial acute response to
stresses that put tissue integrity at risk, but lastingly persistent
senescent cells, for the reasons of pro-inflammatory SASP and
potential senescence escape of SAS+ tumor cells, represent a
dangerous population one would rather like to selectively elim-
inate, if not cleared by host immunity anyway53. Consistently, we
found here the particularly senescence-susceptible GCB subtype
to present with features of an ATSC signature, underscoring the
consideration of a “senolytic” approach at least in this subgroup.
Since we reported the first successful, survival-prolonging
demonstration of a senolytic strategy in cancer, specifically in
the Eµ-myc lymphoma model, in vivo a few years ago25, we are
currently extending our DLBCL-focused studies to this question.
In essence, TIS serves as an important back-up cell-cycle exit
program especially in tumors where apoptosis is no longer
available, but long-term persistence of senescent cells may evoke
aggressive tumor properties if not effectively countered by a
preventive senolytic intervention32.
By introducing a primary transgenic lymphoma model with
defined genetic lesions to interrogate distinct biologies—as pre-
sented here for the Suv39h1-dependent induction of cellular
senescence in response to therapy—followed by the exploration of
a genetically unbiased clinical trial-like mouse lymphoma cohort,
all in a syngeneic, immune-competent context, we provide a
DLBCL-approximated test platform for functional investigations.
While a large body of literature underscores the successful
Fig. 6 The SUVARness gene signature is predictive for treatment outcome in DLBCL. a GSEA profiles of TIS up-regulated (SUVARness) genes as shown
in Fig. 5a probing Eµ-myc;bcl2 lymphomas TIS vs. untreated in vitro (outer left), SENS Eµ-myc lymphomas NR vs. RP (left), and DLBCL patients cured vs.
relapsed in two cohorts (GSE31312, GSE98588; right). b Tumor-free survival in SENS Eµ-myc lymphomas stratified by average expression levels (n= 38
each arm) of the 22 core SUVARness genes (cf. Table S1) commonly selected from the GSEA leading edges (region from the top of the gene list to the
enrichment score profile peak position) in (a). c Same as in (b), applying a fully humanized version of the core SUVARness classifier, showing PFS of R-
CHOP-treated DLBCL patients (GSE98588). Above median: n= 49 (black line), below median: n= 47 (grey line). d OS for patients stratified as in (c).
e GSEA results of core SUVARness-regulated genes in the recently reported newly defined molecular DLBCL cluster subtypes C0–C5 (ref. 14), comparing
each cluster vs. the others. According to Chapuy et al., patients in clusters C0/C1/C4, here marked as SUVARness-enriched, had a significantly better PFS
compared to patients in clusters C3/C5 (ref. 14). n= 137 (n= 6 C0, n= 29 C1, n= 32 C1, n= 28 C3, n= 21 C4, n= 21 C5). f Circular workflow of functional
interrogations in mouse models of cancer harboring defined genetic lesions, investigation of genetically unmanipulated mouse tumors in a clinical trial-like
setting in vivo, and cross-species application of the genetic determinants of novel biological functions and intervention-evoked dynamic state switches
learned therein in corresponding human cancer patient cohorts.
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exploration of functional lymphoma features in Eµ-myc mice and
the subsequent validation of these findings in human
DLBCL23,27,28,40,54–56, we certainly acknowledge limitations of
this transgenic model as a reflection of DLBCL pathogenesis,
particularly in light of numerous mouse models developed to
more faithfully recapitulate GCB- or ABC-subtype features of
human DLBCL57–68. However, while those models elegantly
provide examples for distinct routes into GCB- or ABC-skewed
diffuse large B-cell lymphomagenesis, they are, in turn, selectively
composed of complexity-reduced genetics out of the over-
whelming heterogeneity human DLBCL exhibit as a cardinal
property. In contrast, initiated by a single myc transgene, it is
probably exactly this broad spectrum of early to rather mature B-
cell lymphomas and their diverse secondary hits which accounts
for a heterogeneity in the Eµ-myc model that seems to recapi-
tulate at least some critical features of the heterogeneous DLBCL
transcriptomes40,54. Those resulting Eµ-myc transgenics-derived
genetic determinants can be faithfully re-applied to human
clinically and molecularly co-annotated datasets to identify
hitherto unknown patient subgroups and to unveil the predictive
implication of a certain biological response that a (sizeable)
fraction of the newly diagnosed patients will experience in the
course of their yet-to-start treatment (Fig. 6f). Of note, any gene
candidate emerging from the human data analysis can be re-
fueled into the system to launch a next translational cycle of
functional studies in the mouse that will further deepen molecular
insights into the tumor-treatment interplay, and eventually refine
patient strategies in the clinic. Taken together, our approach
highlights how functional mouse models inform decision making
in cancer precision medicine beyond mutational analyses and
expression profiling of the patient material.
Methods
For the list of primers, details of microarray data processing and subsequent gene
expression analysis, please see Supplementary methods.
Mouse strains and lymphoma generation. All animal protocols used in this study
were approved by the governmental review board (Landesamt Berlin), and conform
to the appropriate regulatory standards. All mice are in a C57BL/6 strain background.
Eµ-myc transgenic lymphomas with defined genetic defects in the suv39h1 or p53
locus were generated by cross-breeding to suv39h1 or p53 knockout mice23,25,28.
Genotyping and semiquantitative detection of the Eµ-myc transgene were carried by
transgene-specific genomic PCR20 and primers are listed in the Supplementary
Information. Inducible Suv39h1 Myc-driven lymphomas were generated from
Suv39h1− Eµ-myc lymphomas stably transduced with a 4-hydroxy-Tamoxifen (4-
OHT)-inducible Suv39h1/estrogen receptor fusion cDNA (Suv39h1:ER)28.
In vivo-treatments and mouse imaging. Individual lymphomas were propagated
in up to two strain-matched, non-transgenic (i.e., genetically non-engineered wild-
type), fully immuno-competent 6–8-week-old mice each via tail vein injection of
106 viable cells (notably, in rare cases, discordant NR/RP responses of the two
same-lymphoma recipients may produce unequal medians of the stratified
response groups). Recipient mice were treated with a single intraperitoneal dose of
cyclophosphamide (CTX, Sigma, 300 mg/kg body weight) or CHOP (i.e., 150
mg/kg CTX, 3.3 mg/kg ADR, 0.5 mg/kg Vincristine, and 200 µg/kg Prednisone) at
the time well-palpable LN enlargements (i.e., about 8–10 mm in diameter) had
formed. Regarding the CHOP regimen, each drug was administered on day 1,
followed by daily administration of Prednisone alone over the next 4 days, con-
sistent with the schedule used in the clinic. Treatment responses were monitored
during regular visits (at least twice a week; for a maximum of a 100-day observation
period), which always included a general inspection of the mice and palpation of
the typically affected LN regions (i.e. cervical, pre-scapular/axillar and inguinal) as
time-to-relapse (TTR), i.e., progression-free survival (PFS), or reflect the time
between treatment and unexpected death of the animal or a preterminal disease
stage, collectively measured as overall survival (OS)20. After CO2 euthanasia, LN,
and in some experiments also the spleen or BM, were isolated to generate tissue
sections or single-cell suspensions20. In vivo-animal imaging was performed as
whole-body luciferase or GFP imaging using a LAS 4000 luminescence and
fluorescence live imaging system (Fujifilm)25.
Cell culture, retroviral infection, and in vitro-treatments. LC were cultured on
irradiated NIH3T3 fibroblasts serving as feeder cells20. Retroviral gene transfer was
carried out with infectious supernatant from murine stem cell retrovirus (MSCV)-
transfected Phoenix packaging cells24. Full-length cDNAs of Lsd1 and Jmjd2c were
purchased from GE Healthcare Dharmacon and subcloned into the MSCV back-
bone co-encoding a puromycin antibiotic resistance gene. Bcl2 was subcloned into
MSCV co-expressing GFP. In vitro drug assays were performed using adriamycin
(ADR), a topoisomerase II inhibitor, at a concentration of 0.05 µg/ml, unless
otherwise indicated.
Analysis of cell viability, cell-cycle, and senescence. Viability and cell numbers
were analyzed by trypan blue dye exclusion. Cell-cycle status was measured via
incorporation of BrdU and PI labeling by flow cytometry23,24. Ki67 was visualized
by immunohistochemistry as an indicator of cell proliferation, and SA-β-gal
activity at pH 5.5 was assessed as a senescence marker in cytospin preparations or
cryosections22,34. The JMJD2 inhibitor IOX1 came from Sigma, the LSD1 inhibitor
2-PCPA-1a was purchased from Uorsy, Ukraine (BBV27286962)45.
Immunoblotting and immunohistochemistry. Immunoblotting (IB) and immu-
nohistochemistry (IHC) were performed as described previously20,27. Antigen
detection by IB was carried out with antibodies against γ-H2AX (Cell Signaling
Technology [CST], #9718, 1:1000 dilution), p53-P-Ser18 (CST, #9284S, 1:1000),
p53 (Leica Biosystems, #NCL-p53-CM5p, 1:1000), p16INK4a (Santa Cruz Bio-
technology, #sc-1661, 1:1000), H3K9me3 (Abcam, #ab8898, 1:1000), LSD1 (CST,
#2184S, 1:1000), JMJD2C (Abcam, #ab85454, 1:1000) and α-Tubulin (Sigma,
#T5168, 1:1000). Anti-mouse or anti-rabbit horseradish peroxidase-conjugated
antibodies were used as secondary antibodies (GE Healthcare, #RPN4301, 1:1000
and #NA931V, 1:2000, respectively). Antigen detection by IHC was performed
with antibodies against Ki67 (Dako, TEC3, 1:1000) and H3K9me3 (Abcam,
#ab8898, 1:1000).
Transcriptome profiling. RNA was isolated from LC using the RNAeasy Mini kit
(Qiagen) and hybridized to Affymetrix Mouse Gene 1.0 ST or Genome 430 2.0
microarrays according to the manufacturer’s instructions. Arrays were hybridized,
washed and scanned by standard Affymetrix protocols. Further processing of the
raw microarray data is described below.
Statistics and data analysis. Based on previous experience with the Eµ-myc
transgenic mouse lymphoma model, sample sizes typically reflect three to five, in
some experiments also much higher numbers of individual primary tumors as
biological replicates. For assessing long-term outcome after in vivo-treatments,
seven or more tumor-bearing animals per arm were used. Survival analysis (Figs. 1b,
d and 2c, d; 3b, c3; 4c and e–h; 5e; and 6b–d) was done using the survival package in
R. Statistical significance of differences in the survival times were assessed using the
log-rank test. All quantifications from staining reactions were carried out by an
independent and blinded second examiner and reflect at least three samples with at
least 100 events counted (typically in three different areas) each, and a t test was
applied. Unless otherwise stated, a p value < 0.05 was considered statistically sig-
nificant. For multiple testing corrections the method by Benjamini and Hochberg
(BH) to control for false-discovery rate was applied69. Bioinformatics Analysis was
performed in R 3.5.0 & Bioconductor 3.7 using various R packages as described in
the Supplemental Experimental Procedures in greater detail. In order to ensure
reproducible results, the R workspace was initiated with a random seed of 1.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The mouse model-derived raw microarray data—from our previously published control;
bcl2, Suv39h1−;bcl2 and Suv39h1−;bcl2 transduced with 4OHT-inducible Suv39h1
(Suv39h1:ER;bcl2) lymphomas25,28 – were deposited at the Gene Expression Omnibus
(GEO) repository of the National Center for Biotechnology Information under accession
number (GSE134753). Data from our clinical-trial like model were deposited under
accession number (GSE134751). Expression data of 39 primary Eµ-myc lymphomas from
our clinical trial-like model were combined with expression profiles from publicly
available primary Eµ-myc lymphoma (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE40760). Expression data of DLBCL patients are publicly available from NCBI
GEO, comprising GSE10846, (GSE4475), (GSE4732) and (GSE31312). In addition, GEP
of DLBCL patients from the Shipp lab for CCC DLBCL distinction were obtained from
https://portals.broadinstitute.org/cgi-bin/cancer/publications/pub_paper.cgi?
mode=view&paper_id=102 (ref. 44) and for GSE98588 from NCBI GEO14. Raw CEL
files were downloaded and processed using RMA implemented in the R package oligo
and batch effects between scan dates reduced using ComBat in the sva package.
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